PT3277677T - Compostos de 1-ciano-pirrolidina como inibidores de usp30 - Google Patents
Compostos de 1-ciano-pirrolidina como inibidores de usp30Info
- Publication number
- PT3277677T PT3277677T PT167130434T PT16713043T PT3277677T PT 3277677 T PT3277677 T PT 3277677T PT 167130434 T PT167130434 T PT 167130434T PT 16713043 T PT16713043 T PT 16713043T PT 3277677 T PT3277677 T PT 3277677T
- Authority
- PT
- Portugal
- Prior art keywords
- cyano
- pyrrolidine compounds
- usp30 inhibitors
- usp30
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/14—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Pyridine Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1505429.9A GB201505429D0 (en) | 2015-03-30 | 2015-03-30 | Novel compounds |
| GBGB1512829.1A GB201512829D0 (en) | 2015-07-21 | 2015-07-21 | Novel compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3277677T true PT3277677T (pt) | 2021-04-20 |
Family
ID=55646790
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT167130434T PT3277677T (pt) | 2015-03-30 | 2016-03-24 | Compostos de 1-ciano-pirrolidina como inibidores de usp30 |
Country Status (29)
| Country | Link |
|---|---|
| US (6) | US10343992B2 (pt) |
| EP (3) | EP3842427A1 (pt) |
| JP (3) | JP6708661B2 (pt) |
| KR (1) | KR102578325B1 (pt) |
| CN (2) | CN112707893B (pt) |
| AU (1) | AU2016240033B2 (pt) |
| BR (1) | BR112017020900B1 (pt) |
| CA (1) | CA2976741C (pt) |
| CO (1) | CO2017011172A2 (pt) |
| CY (1) | CY1124170T1 (pt) |
| DK (1) | DK3277677T3 (pt) |
| ES (1) | ES2864950T3 (pt) |
| HK (1) | HK1245266A1 (pt) |
| HR (1) | HRP20210791T2 (pt) |
| HU (1) | HUE054474T2 (pt) |
| IL (1) | IL254721B (pt) |
| LT (1) | LT3277677T (pt) |
| MD (1) | MD3277677T2 (pt) |
| MX (1) | MX2017012566A (pt) |
| MY (1) | MY188957A (pt) |
| NZ (1) | NZ736450A (pt) |
| PL (1) | PL3277677T3 (pt) |
| PT (1) | PT3277677T (pt) |
| RS (1) | RS61759B9 (pt) |
| RU (1) | RU2717238C2 (pt) |
| SG (1) | SG11201706542TA (pt) |
| SI (1) | SI3277677T1 (pt) |
| WO (1) | WO2016156816A1 (pt) |
| ZA (1) | ZA201705717B (pt) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201416754D0 (en) | 2014-09-23 | 2014-11-05 | Mission Therapeutics Ltd | Novel compounds |
| CN112707893B (zh) * | 2015-03-30 | 2023-10-31 | 特殊治疗有限公司 | 作为usp30抑制剂的1-氰基吡咯烷化合物 |
| GB201521109D0 (en) * | 2015-11-30 | 2016-01-13 | Mission Therapeutics Ltd | Novel compounds |
| GB201522267D0 (en) | 2015-12-17 | 2016-02-03 | Mission Therapeutics Ltd | Novel compounds |
| GB201522768D0 (en) | 2015-12-23 | 2016-02-03 | Mission Therapeutics Ltd | Novel compounds |
| GB201602854D0 (en) * | 2016-02-18 | 2016-04-06 | Mission Therapeutics Ltd | Novel compounds |
| GB201603779D0 (en) | 2016-03-04 | 2016-04-20 | Mission Therapeutics Ltd | Novel compounds |
| GB201604638D0 (en) * | 2016-03-18 | 2016-05-04 | Mission Therapeutics Ltd | Novel compounds |
| GB201604647D0 (en) | 2016-03-18 | 2016-05-04 | Mission Therapeutics Ltd | Novel compounds |
| MA43753A (fr) | 2016-03-24 | 2018-11-28 | Mission Therapeutics Ltd | Dérivés 1-cyano-pyrrolidine comme inhibiteurs de dbu |
| JP6959332B2 (ja) | 2016-09-27 | 2021-11-02 | ミッション セラピューティクス リミティド | Ｕｓｐ３０の阻害剤としての活性を有するシアノピロリジン誘導体 |
| GB201616511D0 (en) | 2016-09-29 | 2016-11-16 | Mission Therapeutics Limited | Novel compounds |
| GB201616627D0 (en) | 2016-09-30 | 2016-11-16 | Mission Therapeutics Limited | Novel compounds |
| TWI771327B (zh) | 2016-10-05 | 2022-07-21 | 英商使命醫療公司 | 新穎化合物 |
| JOP20190072A1 (ar) * | 2016-10-13 | 2019-04-07 | Glaxosmithkline Ip Dev Ltd | مشتقات 1، 3 سيكلوبوتان ثنائي الاستبدال أو آزيتيدين كمثبطات للإنزيم المخلق للبروستاجلاندين d المكون للدم |
| WO2018213150A1 (en) * | 2017-05-15 | 2018-11-22 | Mitobridge, Inc. | Usp30 inhibitors |
| GB201708652D0 (en) | 2017-05-31 | 2017-07-12 | Mission Therapeutics Ltd | Novel compounds and uses |
| EP3642196B1 (en) * | 2017-06-20 | 2022-08-17 | Mission Therapeutics Limited | Substituted cyanopyrrolidines with activity as dub inhibitors |
| EA202090871A1 (ru) * | 2017-10-06 | 2020-07-03 | Форма Терапьютикс, Инк. | Ингибирование убиквитин-специфической пептидазы 30 |
| CN112513036B (zh) * | 2018-05-17 | 2024-05-24 | 福马治疗有限公司 | 用作泛素特异性肽酶30抑制剂的稠合双环化合物 |
| JP7434285B2 (ja) * | 2018-08-14 | 2024-02-20 | アムジエン・インコーポレーテツド | Ｎ－シアノ－７－アザノルボルナン誘導体及びその使用 |
| AU2019356011A1 (en) | 2018-10-05 | 2021-04-01 | Forma Therapeutics, Inc. | Fused pyrrolines which act as ubiquitin-specific protease 30 (USP30) inhibitors |
| CN113453679A (zh) | 2018-12-20 | 2021-09-28 | C4医药公司 | 靶向蛋白降解 |
| GB201905375D0 (en) | 2019-04-16 | 2019-05-29 | Mission Therapeutics Ltd | Novel compounds |
| GB201905371D0 (en) | 2019-04-16 | 2019-05-29 | Mission Therapeutics Ltd | Novel compounds |
| GB201912674D0 (en) * | 2019-09-04 | 2019-10-16 | Mission Therapeutics Ltd | Novel compounds |
| EP4126853A1 (en) * | 2020-03-30 | 2023-02-08 | The Scripps Research Institute | Small molecule inhibitors of influenza hemagglutinin |
| CN111303128B (zh) * | 2020-04-07 | 2020-10-27 | 苏州信诺维医药科技有限公司 | 一种多环类化合物、其制备方法及应用 |
| CA3171349A1 (en) | 2020-04-08 | 2021-10-14 | Mission Therapeutics Limited | N-cyanopyrrolidines with activity as usp30 inhibitors |
| BR112022020644A2 (pt) | 2020-05-28 | 2022-12-06 | Mission Therapeutics Ltd | Derivados de n-(1-ciano-pirrolidin-3-il)-5-(3-(trifluorometil)fenil) oxazol-2-carboxamida e os correspondentes derivados de oxadiazol como inibidores de usp30 para o tratamento de disfunção mitocondrial |
| JP2023529570A (ja) | 2020-06-04 | 2023-07-11 | ミッション セラピューティクス リミティド | Ｕｓｐ３０阻害剤としての活性を有するｎ－シアノピロリジン |
| CN115836073B (zh) * | 2020-06-08 | 2024-08-27 | 特殊治疗有限公司 | 用于治疗线粒体功能障碍、癌症和纤维化的作为usp30抑制剂的1-(5-(2-氰基吡啶-4-基)噁唑-2-羰基)-4-甲基六氢吡咯并[3,4-b]吡咯-5(1h)-甲腈 |
| GB202016800D0 (en) | 2020-10-22 | 2020-12-09 | Mission Therapeutics Ltd | Novel compounds |
| US20240059673A1 (en) * | 2020-12-22 | 2024-02-22 | Gilead Sciences, Inc. | Substituted indole compounds |
| CR20230478A (es) | 2021-04-16 | 2023-11-30 | Gilead Sciences Inc | Compuestos de tienopirrol. |
| CA3230800A1 (en) | 2021-09-10 | 2023-03-16 | Gilead Sciences, Inc. | Thienopyrrole compounds |
| AU2022362107A1 (en) | 2021-10-11 | 2024-05-02 | Anebulo Pharmaceuticals, Inc. | Crystalline forms of a cannabinoid receptor type 1 (cb1) modulator and methods of use and preparation thereof |
| EP4441044A1 (en) | 2021-12-01 | 2024-10-09 | Mission Therapeutics Limited | Substituted n-cyanopyrrolidines with activity as usp30 inhibitors |
| WO2024086708A2 (en) * | 2022-10-19 | 2024-04-25 | Ohio State Innovation Foundation | Compositions and methods for preventing cardiomyopathy |
| WO2024182384A1 (en) * | 2023-02-28 | 2024-09-06 | Cyteir Therapeutics, Inc. | Substituted pyrrolidine and pyrrolidinone compounds |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5665754A (en) | 1993-09-20 | 1997-09-09 | Glaxo Wellcome Inc. | Substituted pyrrolidines |
| US6187797B1 (en) | 1996-12-23 | 2001-02-13 | Dupont Pharmaceuticals Company | Phenyl-isoxazoles as factor XA Inhibitors |
| AU2001256981A1 (en) * | 2000-04-06 | 2001-10-23 | Axys Pharmaceuticals, Inc. | Cathepsin cysteine protease inhibitors |
| AU2003263393A1 (en) | 2002-09-04 | 2004-03-29 | Glenmark Pharmaceuticals Limited | New heterocyclic amide compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them |
| CA2752738C (en) * | 2005-02-22 | 2014-05-27 | The Regents Of The University Of Michigan | Small molecule inhibitors of mdm2 and uses thereof |
| PE20091843A1 (es) * | 2008-04-18 | 2010-01-07 | Glaxo Group Ltd | Inhibidores de catepsina c |
| CN104610230A (zh) | 2008-06-16 | 2015-05-13 | 田纳西大学研究基金会 | 用于治疗癌症的化合物 |
| US8354444B2 (en) * | 2008-09-18 | 2013-01-15 | Hoffmann-La Roche Inc. | Substituted pyrrolidine-2-carboxamides |
| US8598209B2 (en) | 2008-10-31 | 2013-12-03 | Merck Sharp & Dohme Corp. | P2X3, receptor antagonists for treatment of pain |
| EP2410858B1 (en) | 2009-03-23 | 2016-09-07 | Merck Sharp & Dohme Corp. | P2x3 receptor antagonists for treatment of pain |
| CA2811567C (en) | 2010-09-24 | 2019-09-10 | The Regents Of The University Of Michigan | Deubiquitinase inhibitors and methods for use of the same |
| AU2012326682B2 (en) * | 2011-10-19 | 2016-02-18 | Vivolux Ab | Method for inhibition of deubiquitinating activity |
| MX358660B (es) | 2012-01-12 | 2018-08-30 | Univ Yale | Compuestos y metodos para degradacion mejorada de proteinas y otros polipeptidos elegidos como blanco mediante una ubiquitina ligasa e3. |
| CA2904393A1 (en) | 2013-03-15 | 2014-09-25 | Araxes Pharma Llc | Covalent inhibitors of kras g12c |
| WO2016019237A2 (en) | 2014-07-31 | 2016-02-04 | Pharmacyclics Llc | Inhibitors of bruton's tyrosine kinase |
| US10160727B2 (en) | 2014-08-06 | 2018-12-25 | Shionogi & Co., Ltd. | Heterocycle and carbocycle derivatives having TrkA inhibitory activity |
| GB201416754D0 (en) * | 2014-09-23 | 2014-11-05 | Mission Therapeutics Ltd | Novel compounds |
| CN112707893B (zh) | 2015-03-30 | 2023-10-31 | 特殊治疗有限公司 | 作为usp30抑制剂的1-氰基吡咯烷化合物 |
| WO2017009650A1 (en) | 2015-07-14 | 2017-01-19 | Mission Therapeutics Limited | Cyanopyrrolidines as dub inhibitors for the treatment of cancer |
| GB201521109D0 (en) | 2015-11-30 | 2016-01-13 | Mission Therapeutics Ltd | Novel compounds |
| GB201522267D0 (en) | 2015-12-17 | 2016-02-03 | Mission Therapeutics Ltd | Novel compounds |
| GB201522768D0 (en) * | 2015-12-23 | 2016-02-03 | Mission Therapeutics Ltd | Novel compounds |
| GB201602854D0 (en) * | 2016-02-18 | 2016-04-06 | Mission Therapeutics Ltd | Novel compounds |
| GB201603779D0 (en) | 2016-03-04 | 2016-04-20 | Mission Therapeutics Ltd | Novel compounds |
| GB201604647D0 (en) | 2016-03-18 | 2016-05-04 | Mission Therapeutics Ltd | Novel compounds |
| GB201604638D0 (en) | 2016-03-18 | 2016-05-04 | Mission Therapeutics Ltd | Novel compounds |
| MA43753A (fr) | 2016-03-24 | 2018-11-28 | Mission Therapeutics Ltd | Dérivés 1-cyano-pyrrolidine comme inhibiteurs de dbu |
| JP6959332B2 (ja) * | 2016-09-27 | 2021-11-02 | ミッション セラピューティクス リミティド | Ｕｓｐ３０の阻害剤としての活性を有するシアノピロリジン誘導体 |
-
2016
- 2016-03-24 CN CN202110132842.2A patent/CN112707893B/zh active Active
- 2016-03-24 ES ES16713043T patent/ES2864950T3/es active Active
- 2016-03-24 EP EP21156385.3A patent/EP3842427A1/en active Pending
- 2016-03-24 JP JP2017551189A patent/JP6708661B2/ja active Active
- 2016-03-24 LT LTEP16713043.4T patent/LT3277677T/lt unknown
- 2016-03-24 MY MYPI2017001206A patent/MY188957A/en unknown
- 2016-03-24 CA CA2976741A patent/CA2976741C/en active Active
- 2016-03-24 CN CN201680019213.6A patent/CN107484415B/zh active Active
- 2016-03-24 SG SG11201706542TA patent/SG11201706542TA/en unknown
- 2016-03-24 EP EP21190809.0A patent/EP3943490A1/en active Pending
- 2016-03-24 WO PCT/GB2016/050851 patent/WO2016156816A1/en active Application Filing
- 2016-03-24 MD MDE20180120T patent/MD3277677T2/ro unknown
- 2016-03-24 SI SI201631157T patent/SI3277677T1/sl unknown
- 2016-03-24 EP EP16713043.4A patent/EP3277677B9/en active Active
- 2016-03-24 AU AU2016240033A patent/AU2016240033B2/en active Active
- 2016-03-24 HU HUE16713043A patent/HUE054474T2/hu unknown
- 2016-03-24 PT PT167130434T patent/PT3277677T/pt unknown
- 2016-03-24 NZ NZ736450A patent/NZ736450A/en unknown
- 2016-03-24 MX MX2017012566A patent/MX2017012566A/es active IP Right Grant
- 2016-03-24 KR KR1020177031166A patent/KR102578325B1/ko active IP Right Grant
- 2016-03-24 DK DK16713043.4T patent/DK3277677T3/da active
- 2016-03-24 RS RS20210502A patent/RS61759B9/sr unknown
- 2016-03-24 US US15/558,632 patent/US10343992B2/en active Active
- 2016-03-24 RU RU2017134901A patent/RU2717238C2/ru active
- 2016-03-24 PL PL16713043T patent/PL3277677T3/pl unknown
- 2016-03-24 BR BR112017020900-4A patent/BR112017020900B1/pt active IP Right Grant
-
2017
- 2017-08-22 ZA ZA2017/05717A patent/ZA201705717B/en unknown
- 2017-09-26 IL IL254721A patent/IL254721B/en active IP Right Grant
- 2017-10-30 CO CONC2017/0011172A patent/CO2017011172A2/es unknown
-
2018
- 2018-04-10 HK HK18104692.3A patent/HK1245266A1/zh unknown
-
2019
- 2019-03-11 US US16/297,937 patent/US11053198B2/en active Active
- 2019-05-22 US US16/419,747 patent/US11066365B2/en active Active
- 2019-05-22 US US16/419,558 patent/US10689345B2/en active Active
-
2020
- 2020-02-12 US US16/788,446 patent/US11390584B2/en active Active
- 2020-05-21 JP JP2020088995A patent/JP7216682B2/ja active Active
-
2021
- 2021-05-17 HR HRP20210791TT patent/HRP20210791T2/hr unknown
- 2021-05-20 CY CY20211100441T patent/CY1124170T1/el unknown
-
2022
- 2022-03-31 US US17/709,556 patent/US20220251041A1/en active Pending
- 2022-06-21 JP JP2022099677A patent/JP7389856B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1245266A1 (zh) | 作為usp30抑制劑的1-氰基吡咯烷化合物 | |
| IL250709A0 (en) | Aminopyrimidines and their use to inhibit jak | |
| IL246785A0 (en) | Benzimidazole-2-amines as midh1 inhibitors | |
| HK1226398A1 (zh) | 作為midh1抑制劑的苯並咪唑-2-胺 | |
| GB201510019D0 (en) | Compounds | |
| IL251780A0 (en) | New compounds as nik inhibitors | |
| GB201513481D0 (en) | Inhibitor compounds | |
| GB201505658D0 (en) | Inhibitor compounds | |
| GB201508747D0 (en) | Compounds | |
| GB201501004D0 (en) | Inhibitors | |
| GB201508864D0 (en) | Compounds | |
| GB201510493D0 (en) | Compounds | |
| GB201520949D0 (en) | Inhibitors | |
| GB201508857D0 (en) | Compounds | |
| GB201503926D0 (en) | Compounds | |
| GB201501115D0 (en) | Compounds | |
| GB201522453D0 (en) | Inhibitor compounds | |
| GB201520189D0 (en) | Compound for use | |
| GB201500644D0 (en) | Inhibitor compounds | |
| GB201510760D0 (en) | Compounds | |
| GB201508866D0 (en) | Compounds | |
| GB201508453D0 (en) | Compounds | |
| GB201508454D0 (en) | Compounds | |
| GB201505676D0 (en) | Compounds | |
| GB201505675D0 (en) | Compounds |